Integration of Oxytocin into the Cold Chain of the Expanded Programme on Immunization: Case of Mali. September 2014
(2014; 40 pages) [French]

Pachuto, MW, Yeager B, Diarra S, Doumbia M and Sangho A. 2014. Integration of Oxytocin into the Cold Chain of the Expanded Programme on Immunization: The Case of Mali. Submitted to the US Agency for International Development by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program. Arlington, VA: Management Sciences for Health.

Abrégé

Postpartum hemorrhage (PPH) still remains one of the major causes of maternal mortality, accounting for 35% of all maternal deaths. The World Health Organization (WHO) has recommended oxytocin as the most effective medicine for the prevention and treatment of PPH, particularly for facility-based births. Most countries include oxytocin on their essential medicines lists (EML) as the medicine of choice for prevention and treatment of PPH. In most countries, several oxytocin products are registered. Despite this positive policy framework for oxytocin use, supply chain barriers that limit access to the medicine still persist in many countries. The factors that contribute to this lack of availability include inadequate forecasting of requirements, weak information systems, and poor distribution systems. Another major challenge is maintaining proper storage conditions throughout the supply chain. Oxytocin requires storage at between 2 and 8 °C, with possible excursions to room temperature for brief time periods. However, the distribution systems in many countries do not allow for cold storage.

 
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 29 octobre 2018